NAD+ Injections vs. IV Therapy vs. Nasal Spray: Pros, Cons, and Differences

Short answer: IV NAD+/NR has the strongest human data (with NR often better tolerated than direct NAD+); subcutaneous injection has a plausible rationale but thin published PK data; nasal spray has no published human absorption studies for NAD+ itself.

NAD+ is available through several different delivery routes, and the marketing often implies they're roughly interchangeable — just pick whichever's most convenient. The actual evidence tells a more specific story: some routes have real human data behind them, and one — the one increasingly marketed as the "easy" option — has essentially none for this particular molecule.

The Three Routes at a Glance

NAD+ and its precursors are delivered through several routes in clinical and wellness settings: subcutaneous injection, intravenous (IV) infusion, and intranasal spray — each with distinct absorption profiles, sensory experiences, and evidence bases.

IV Infusion: The Most Direct Human Data, With Real Trade-Offs

IV infusion delivers NAD+ or its precursors directly into the bloodstream, bypassing digestive breakdown entirely. Two independent studies — a randomized, placebo-controlled pilot trial and a separate 2026 retrospective real-world review of clinic records — both point the same direction, which is a genuinely reassuring form of agreement across different study designs.

The randomized trial found direct IV NAD+ infusion produced universal, moderate-to-severe adverse effects during the infusion itself — abdominal cramping, diarrhea, nausea, vomiting, increased heart rate, throat pain, congestion, and chest pressure. That same trial found infused nicotinamide riboside (NR, a NAD+ precursor) was significantly better tolerated than direct NAD+ IV, with fewer and less severe side effects — and NR infusions took roughly 60% less time to administer while still producing a superior rise in blood NAD+ levels at the 3-hour mark. All reported adverse effects resolved immediately once the infusion finished, and no serious adverse events occurred in either group.

The separate 2026 retrospective study, reviewing real-world electronic medical records from a commercial wellness clinic, independently found the same pattern: NAD+ IV was less well-tolerated than NR IV.^[1]Worth noting precisely: this second study is a retrospective chart review, not a randomized trial — a real-world confirmation that adds weight to the RCT finding, but it's a different, somewhat less rigorous type of evidence.

Subcutaneous Injection: A Plausible Rationale, Genuinely Thin Data

This route delivers NAD+ in smaller volumes directly under the skin, and researchers generally assume it also bypasses gastrointestinal degradation the way IV does. But it's worth being straightforward here: formal human pharmacokinetic data for subcutaneous NAD+ specifically — tissue concentration, half-life, direct comparison to IV at equivalent doses — simply wasn't found in the peer-reviewed literature searched for this article. That's not the same as evidence against it; it's an honest gap in what's been published so far.

Nasal Spray: Where the Evidence Runs Out

Intranasal delivery genuinely does offer real advantages for the right kind of molecule — small and lipophilic (fat-soluble). It bypasses gastrointestinal and hepatic first-pass metabolism, and the nasal mucosa's large, richly vascularized surface area can enable rapid systemic absorption.^[2]

The problem is that NAD+ isn't that kind of molecule. The nasal route has well-documented physical limits: only a small volume (roughly 100–150 microliters per nostril) can be administered per dose, and the nasal mucus layer is cleared and renewed by ciliary action roughly every 10–20 minutes — limiting how long a drug actually has to absorb before being swept away.^[3]Peer- reviewed pharmacology reviews establish that intranasal bioavailability drops sharply as a drug's molecular weight increases, and for hydrophilic peptides and proteins specifically, nasal bioavailability is typically well under 1%.^[3]

NAD+ is a relatively large, charged, water-soluble molecule (approximately 664 daltons) — exactly the molecular profile that research has repeatedly shown struggles to cross the nasal mucosa efficiently without specialized absorption-enhancing technology that current NAD+ nasal products don't appear to use.

As of this writing, no published, peer-reviewed human clinical trial has directly measured intranasal NAD+'s systemic or brain-level absorption. That means claims about nasal spray NAD+ effectiveness currently rely on extrapolation from how other, smaller drugs behave nasally — not direct pharmacokinetic data for NAD+ itself.

Weighing the Three Routes

Comparing providers? SeeNAD+ Therapy prices across Longevity providerson RENVA's Longevity hub.

The Bottom Line

If you're choosing based on what's actually been studied in humans, IV infusion — particularly with an NAD+ precursor like NR rather than direct NAD+ — currently has the most direct evidence behind it, including agreement across two independently designed studies. Subcutaneous injection has a reasonable rationale but hasn't been formally studied for this molecule yet. Nasal spray is the most heavily marketed for convenience, but it's also the route with the least direct evidence specific to NAD+ — worth knowing if effectiveness, not just convenience, is what you're optimizing for.

Frequently Asked Questions